TD Cowen analyst Ritu Baral has maintained their neutral stance on AKRO stock, giving a Hold rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ritu Baral has given her Hold rating due to a combination of factors influencing Akero Therapeutics. The ongoing SYNCHRONY MASH program, which is a critical component of Akero’s research efforts, is progressing with various trials at different stages. The completion of enrollment in the non-biopsy ‘Real-World’ trial and the expected data release in the first half of 2026 are key milestones.
Additionally, the acquisition of Akero by Novo Nordisk for $54 per share in cash, along with a contingent value right (CVR) of $6 per share, is a significant development. This acquisition, which is anticipated to close by the end of 2025 pending necessary approvals, represents a substantial premium over Akero’s recent stock prices. Despite these positive aspects, the financial performance, including a net loss reported in the third quarter of 2025, suggests a cautious approach, justifying the Hold rating.
In another report released today, Canaccord Genuity also maintained a Hold rating on the stock with a $54.00 price target.
Based on the recent corporate insider activity of 140 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKRO in relation to earlier this year.